BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23263913)

  • 1. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
    Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
    Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
    Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
    Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
    Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
    Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
    Liu S; Zhang X; Jiang Q; Liang T
    FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
    Liang T; Han Z; Zhao H; Zhang X; Wang Y
    Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
    Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
    Wang J; Xu Y; Zhao H; Zhang X
    J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated Circulating CD4
    Hu X; Gu Y; Zhao S; Hua S; Jiang Y
    Cancer Biother Radiopharm; 2019 Jun; 34(5):325-333. PubMed ID: 30925076
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
    Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
    Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
    Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
    Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
    Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
    Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of IgA and IgG autoantibodies against Transcriptional Intermediary Factor-1γ contributes to the early diagnosis of Lung Cancer.
    Yu L; Lin X; Zhang L; Wu Q; Zhang S; Chen D; Pan X; Huang Y
    Int J Med Sci; 2020; 17(11):1561-1568. PubMed ID: 32669959
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Du KL; Ji WT; Jiang QH; Wang Y
    Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer.
    Jin Y; Guan S; Liu L; Sun S; Lee KH; Wei J
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e37-41. PubMed ID: 24811068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
    Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
    Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between CD4+CD25+ Treg and expression of HIF-1α and Ki-67 in NSCLC patients.
    He LY; Li L; Guo ML; Zhang Y; Zhang HZ
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1351-5. PubMed ID: 25967708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of Circulating Natural Antibodies Against CD25 and FOXP3 in Type-2 Diabetes.
    Qiu C; Li C; Wu X; Chen X; Zhang X; Meng Q
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
    Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
    Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of circulating antibodies to ANXA1 in breast cancer.
    Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
    Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.